Marvel Biosciences Corp (TSE:MRVL)
:MRVL
Want to see TSE:MRVL full AI Analyst Report?
MRVL Stock Chart & Stats
C$0.14
-C$0.01(-6.45%)
At close: 4:00 PM EST
C$0.14
-C$0.01(-6.45%)
Day’s Range― - ―
52-Week RangeC$0.08 - C$0.40
Previous CloseN/A
Volume5.00K
Average Volume (3M)89.38K
Market Cap
C$9.14M
Enterprise ValueC$12.12M
Total Cash (Recent Filing)C$274.17K
Total Debt (Recent Filing)C$2.31M
Price to Earnings (P/E)―
Beta-0.05
Next Earnings
Jun 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding63,028,290
10 Day Avg. Volume75,294
30 Day Avg. Volume89,378
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-2.07
Price to Sales (P/S)0.00
P/FCF Ratio-7.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Narrowing Net LossesNet losses have contracted versus prior years, signaling progress on expense control or program prioritization. This durable improvement increases operational runway per dollar of funding and reduces near-term dilution risk if sustained, strengthening the company's ability to advance R&D.
Improving Cash Burn TrendOperating and free cash flow remain negative but have meaningfully improved year over year. A sustained reduction in cash burn materially extends financing runway, lowers frequency of capital raises, and provides management more flexibility to execute development milestones with less dilution risk.
Lean Operating StructureA very small headcount implies low fixed overhead and focused resource allocation, which is structurally beneficial for a pre-revenue biotech. Maintaining a lean team reduces cash consumption and allows capital to be concentrated on core programs, extending runway for development.
Bears Say
Negative Shareholder EquitySustained negative equity reflects accumulated losses and eroded capital, constraining borrowing capacity and increasing reliance on dilutive equity financing. For an early-stage biotech, this materially weakens financial flexibility and elevates long-term solvency and refinancing risk.
Pre-revenue Business ModelNo product revenue leaves the company dependent on external financing to fund R&D and operations. This structural reliance on capital markets increases execution risk, ties progress to fundraising conditions, and lengthens time to self-sustaining cash generation.
Ongoing Negative Cash Flow And DebtPersistent negative operating cash flow combined with measurable debt creates refinancing and liquidity risk. Over the medium term, this profile pressures management to secure new capital or restructure obligations, which can dilute shareholders and divert focus from long-term R&D objectives.
Marvel Biosciences Corp News
MRVL FAQ
What was Marvel Biosciences Corp’s price range in the past 12 months?
Marvel Biosciences Corp lowest stock price was C$0.08 and its highest was C$0.40 in the past 12 months.
What is Marvel Biosciences Corp’s market cap?
Marvel Biosciences Corp’s market cap is C$9.14M.
When is Marvel Biosciences Corp’s upcoming earnings report date?
Marvel Biosciences Corp’s upcoming earnings report date is Jun 23, 2026 which is in 27 days.
How were Marvel Biosciences Corp’s earnings last quarter?
Marvel Biosciences Corp released its earnings results on Mar 31, 2026. The company reported -C$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.005.
Is Marvel Biosciences Corp overvalued?
According to Wall Street analysts Marvel Biosciences Corp’s price is currently Overvalued.
Does Marvel Biosciences Corp pay dividends?
Marvel Biosciences Corp does not currently pay dividends.
What is Marvel Biosciences Corp’s EPS estimate?
Marvel Biosciences Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Marvel Biosciences Corp have?
Marvel Biosciences Corp has 63,028,290 shares outstanding.
What happened to Marvel Biosciences Corp’s price movement after its last earnings report?
Marvel Biosciences Corp reported an EPS of -C$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.941%.
Which hedge fund is a major shareholder of Marvel Biosciences Corp?
Currently, no hedge funds are holding shares in TSE:MRVL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Marvel Biosciences Corp
Marvel Biosciences Corp. operates as a pre-clinical stage pharmaceutical development biotechnology company. It engages in the discovery and development of synthetic derivative compounds of known drugs that inhibit the A2a adenosine receptor. The company offers Nourianz (Istradefylline, KW-6002) and MB-204 an adenosine A2A receptor antagonist. It targets neurological diseases, such as Alzheimer's disease, depression and anxiety, and non-neurological conditions of cancer; and non-alcoholic steatohepatitis. Marvel Biosciences Corp. is headquartered in Calgary, Canada.
Technical Analysis
BetterLife Pharma
―
―
Entheon Biomedical
―
Bright Minds Biosciences
―
MYND Life Sciences
―
Options Prices
Currently, No data available
---